Thursday, 15 October 2026European Markets

FERMENTALG Stock Bullish Momentum With A 14.73% Jump Today

Loading stream...

(vianews) - the market ended the session with fermentalg (falg.pa) jumping 14.73% to €0.52 on wednesday while cac 40 fell 0.27% to €7,656.75.

fermentalg's last close was €0.46, 75.72% under its 52-week high of €1.87.

about fermentalg

fermentalg sa develops, produces, and sells active ingredients extracted from microalgae for the food, health, nutrition, and environment sectors in france and internationally. it offers dha origins, a plant-based dha oil; kalvea plus, a nutritious algal protein concentrate dedicated to aquafeed applications; everzure, an extract of natural acid stable blue color; blue origins aox, an antioxidant and anti-inflammatory activities; blue origin, a natural color; and environmental and clean air solutions that captures co2 in industries. the company was incorporated in 2009 and is headquartered in libourne, france.

earnings per share

as for profitability, fermentalg has a trailing twelve months eps of €-0.24.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -24.52%.

volatility

fermentalg's last week, last month's, and last quarter's current intraday variation average was 4.62%, 2.32%, and 5.96%.

fermentalg's highest amplitude of average volatility was 10.19% (last week), 6.42% (last month), and 5.96% (last quarter).

revenue growth

year-on-year quarterly revenue growth declined by 55.4%, now sitting on 4.75m for the twelve trailing months.

sales growth

fermentalg's sales growth for the current quarter is 113.5%.

yearly top and bottom value

fermentalg's stock is valued at €0.52 at 21:33 est, way under its 52-week high of €1.87 and way higher than its 52-week low of €0.21.

more news about fermentalg (falg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com